HIV-positive patients carry an increased risk of HPV infection and associated cancers. Therefore, prevalence and patterns of HPV infection at different anatomical sites, as well as theoretical protection of nonavalent vaccine should be investigated. Aim was to describe prevalence and predictors of oral HPV detection in HIV-positive men, with attention to nonavalent vaccine-targeted HPV types. Further, co-occurrence of HPV DNA at oral cavity and at anal site was assessed.
This cross-sectional, clinic-based study included 305 HIV-positive males (85.9% MSM; median age 44.7 years; IQR: 37.4–51.0), consecutively observed within an anal cancer screening program, after written informed consent. Indication for anal screening was given by the HIV physician during routine clinic visit. Paired oral rinse and anal samples were processed for the all HPV genotypes with QIASYMPHONY and a PCR with MY09/MY11 primers for the L1 region.
At the oral cavity, HPV DNA was detected in 64 patients (20.9%), and in 28.1% of these cases multiple HPV infections were found. Prevalence of oral HPV was significantly lower than that observed at the anal site (p < 0.001), where HPV DNA was found in 199 cases (85.2%). Oral HPV tended to be more frequent in patients with detectable anal HPV than in those without (p = 0.08). Out of 265 HPV DNA-positive men regardless anatomic site, 59 cases (19.3%) had detectable HPV at both sites, and 51 of these showed completely different HPV types. At least one nonavalent vaccine-targeted HPV type was found in 17/64 (26.6%) of patients with oral and 199/260 (76.5%) with anal infection. At multivariable analysis, factors associated with positive oral HPV were: CD4 cells <200/μL (versus CD4 cells >200/μL, p = 0.005) and >5 sexual partners in the previous 12 months (versus 0–1 partner, p = 0.008).
In this study on Italian HIV-positive men (predominantly MSM), oral HPV DNA was detected in approximately one fifth of tested subjects, but prevalence was significantly lower than that observed at anal site. Low CD4 cell count and increasing number of recent sexual partners significantly increased the odds of positive oral HPV. The absence of co-occurrence at the two anatomical sites may suggest different routes or timing of infection.
Vandenhende MA, Roussillon C, Henard S, et al. For ANRS EN20 Mortalité 2010 study group. Cancer-related causes of death among HIV-infected patients in France in 2010: evolution since 2000. PLoS One. 2015;10(6):e0129550. https://doi.org/10.1371/journal.pone.0129550. CrossRefPubMedPubMedCentral
Trickey A, May MT, Vehreschild J, et al. For antiretroviral therapy cohort collaboration (ART-CC). Cause-specific mortality in HIV-positive patients who survived ten years after starting antiretroviral therapy. PLoS One. 2016;11:e0160460. https://doi.org/10.1371/journal.pone.0160460. CrossRefPubMedPubMedCentral
Beachler DC, Abraham AG, Silverberg MJ, for North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA, et al. Incidence and risk factors of HPV-related and HPV-unrelated head and neck Squamous cell carcinoma in HIV-infected individuals. Oral Oncol. 2014;50:1169–76. https://doi.org/10.1016/j.oraloncology.2014.09.011. CrossRefPubMedPubMedCentral
Schache AG, Powell NG, Cuschieri KS, et al. HPV-related Oropharynx cancer in the United Kingdom: an evolution in the understanding of disease etiology. Cancer Res. 2016;76:6598–606. https://doi.org/10.1158/0008-5472.CAN-16-0633. CrossRefPubMed
Kreimer AR, Clifford GM, Boyle P, et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomark Prev. 2005;14:467–75. CrossRef
Parisi SG, Cruciani M, Scaggiante R, et al. Anal and oral human papillomavirus (HPV) infection in HIV-infected subjects in northern Italy: a longitudinal cohort study among men who have sex with men. BMC Infect Dis. 2011;11:150. https://doi.org/10.1186/1471-2334-11-150. CrossRefPubMedPubMedCentral
Read TRH, Hocking JS, Vodstrcil LA, et al. Oral human papillomavirus in men having sex with men:risk factors and sampling. PLoS One. 2012;7:e49324. https://doi.org/10.1371/journal.pone.0049324. CrossRefPubMedPubMedCentral
King EM, Oomeer S, Gilson R, et al. Oral human Papillomavirus infection in men who have sex with men: a systematic review and meta-analysis. PLoS One. 2016:1–15. https://doi.org/10.1371/journal.pone.0157976.
Ucciferri C, Tamburro M, Falasca K, et al. Prevalence of anal, oral, penile and urethral human Papillomavirus in HIV infected and HIV uninfected men who have sex with men. J Med Virol. 2017; https://doi.org/10.1002/jmv.24943.
Wang L, Wang P, Ren Y, et al. Prevalence of high-risk human Papillomavirus (HR-HPV) genotypes and multiple infections in cervical abnormalities from northern Xinjiang, China. PLoS One. 2016;11:e0160698. https://doi.org/10.1371/journal.pone.0160698. CrossRefPubMedPubMedCentral
Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2014;63(RR-05):1–30. Erratum in: MMWR Recomm Rep. 2014 Dec 12;63(49):1182 PubMed
Piano Nazionale Prevenzione Vaccinale 2017–2019. http://www.salute.gov.it/portale/documentazione/p6_2_2_1.jsp?lingua=italiano&id=2571.
Food and Drug Administration. FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV. Dec.2014. https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm426445.htm.
European Medicines Agency. Annexe I. Summary of product characteristics. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003852/human_med_001863.jsp&mid=WC0b01ac058001d124 information/human/003852/WC500189111.pdf.
European AIDS Clinical Society. Guidelines, version 9.0. 2017 http://www.eacsociety.org/files/guidelines_8.2-english.pdf.
Garbuglia AR, Piselli P, Lapa D, et al. Frequency and multiplicity of human papillomavirus infection in HIV-1 positive women in Italy. J Clin Virol. 2012;54:141–6. https://doi.org/10.1016/j.jcv.2012.02.013. CrossRefPubMed
Garbuglia AR, Gentile M, Del Nonno F, et al. An anal cancer screening program for MSM in Italy: prevalence of multiple HPV types and vaccine-targeted infections. J Clin Virol. 2015;72:49–54. https://doi.org/10.1016/j.jcv.2015.09.001. CrossRefPubMed
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum. 2007;90:1–636. PubMedCentral
Papanicolaou GN, Traut HF. The diagnostic value of vaginal smears in carcinoma of the uterus. 1941. Arch Pathol Lab Med. 1997;121:211–24. PubMed
IBM Corp. Released 2015. IBM SPSS statistics for windows, version 23.0. Armonk NY: IBM Corp.
Lupato V, Holzinger D, Höfler D, Menegaldo A, Giorgi Rossi P, Del Mistro A, et al. Prevalence and determinants of oral human Papillomavirus infection in 500 young adults from Italy. PLoS One. 2017;12(1):e0170091. https://doi.org/10.1371/journal.pone.0170091. CrossRefPubMedPubMedCentral
Videla S, Darwick L, Canadas MP, et al. Natural history of human papillomavirus infections involving anal, penile and oral sites among HIV positive men. Sex Transm Dis. 2013;40:3–10. https://doi.org/10.1097/OLQ.0b013e31827e87bd. CrossRefPubMed
King EM, Gilson R, Beddows S, et al. Oral human papillomavirus (HPV) infection in men who have sex with men: prevalence and lack of anogenital concordance. Sex Transm Infect. 2015;91:284–6. https://doi.org/10.1136/sextrans-2014-051955. CrossRefPubMedPubMedCentral
Agalliu I, Wang T, Burk RD. β- and γ-human Papillomavirus types and smoking in head and neck cancer-reply. JAMA Oncol. 2016;2:687–8. https://doi.org/10.1001/jamaoncol.2016.0973. CrossRefPubMed
- Oral human Papillomavirus DNA detection in HIV-positive men: prevalence, predictors, and co-occurrence at anal site
Anna Rosa Garbuglia
Franca Del Nonno
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
e.Med Kampagnen-Visual, Mail Icon II